These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 29407973)
1. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents. Wan Y; Dai N; Tang Z; Fang H Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973 [TBL] [Abstract][Full Text] [Related]
2. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1). Beekman AM; O'Connell MA; Howell LA ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140 [TBL] [Abstract][Full Text] [Related]
3. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800 [TBL] [Abstract][Full Text] [Related]
4. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation. Xu G; Liu T; Zhou Y; Yang X; Fang H Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374 [TBL] [Abstract][Full Text] [Related]
5. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455 [TBL] [Abstract][Full Text] [Related]
6. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors. Wan Y; Li Y; Yan C; Wen J; Tang Z Bioorg Chem; 2020 Nov; 104():104217. PubMed ID: 32911192 [TBL] [Abstract][Full Text] [Related]
7. Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1. Beekman AM; Howell LA ChemMedChem; 2016 Apr; 11(8):802-13. PubMed ID: 26696548 [TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors. Zhu J; Wang Z; Guo Z; Zhang X; Song T; Guo Y; Ji T; Zhang Z Arch Pharm (Weinheim); 2020 May; 353(5):e2000005. PubMed ID: 32175625 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors. Liu L; Liu R; Yang X; Hou X; Fang H Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497 [TBL] [Abstract][Full Text] [Related]
11. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900 [TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein. Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269 [TBL] [Abstract][Full Text] [Related]
13. Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1. Daressy F; Malard F; Seguy L; Guérineau V; Apel C; Dumontet V; Robert A; Groo AC; Litaudon M; Bignon J; Desrat S; Malzert-Fréon A; Wiels J; Lescop E; Roussi F ChemMedChem; 2021 Jun; 16(11):1788-1797. PubMed ID: 33665938 [TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420 [TBL] [Abstract][Full Text] [Related]
15. Mcl-1 as a "barrier" in cancer treatment: Can we target it now? Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition. Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561 [TBL] [Abstract][Full Text] [Related]
17. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia. Besbes S; Pocard M; Mirshahi M; Billard C Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021 [TBL] [Abstract][Full Text] [Related]
18. Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology. Li K Bioorg Med Chem Lett; 2021 Jan; 32():127717. PubMed ID: 33253879 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors. Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718 [TBL] [Abstract][Full Text] [Related]